Document is current
Any future updates will be listed below
-
Authors
Thal, Dietmar Rudolf
De Strooper, Bart
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Stichting Alzheimer Onderzoek (2023/0009)
Alzheimer's Association (22-AAIIA-963171)
Onderzoeksraad, KU Leuven (C14/22/132)
- License Information
-
More Information
Article History
Received: 15 September 2024
Revised: 15 September 2024
Accepted: 18 September 2024
First Online: 24 September 2024
Declarations
:
: DRT receives research grants from FWO (Belgium; Grant Nos. G0F8516N, G065721N), Alzheimer’s Association (USA; Grant No. 22-AAIIA-963171), Stichting Alzheimer Onderzoek (Belgium; Grant No. 2023/0009) and KU-Leuven Internal Funding (Belgium; Grant No. C14/22/132, Opening the future) and collaborates with GE-Healthcare (UK), and Novartis Pharma (Switzerland). B.D.S. is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. B.D.S. is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics.
Free to read: This content has been made available to all.
